Status:
UNKNOWN
Platelet Rich Plasma in Treatment of Melasma
Lead Sponsor:
Assiut University
Conditions:
Melasma
Platelet Rich Plasma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Melasma is a common acquired disorder characterized by symmetric, hyperpigmented patches with an irregular outline, occurring most commonly on the face. The therapy for melasma has always been challen...
Detailed Description
Melasma is a pigmentary disorder that can be disfiguring and can cause to significant emotional stresses for sufferers, for which a universally effective treatment is still lacking. Platelet rich plas...
Eligibility Criteria
Inclusion
- patients with melasma 18 years old or more
Exclusion
- Patients less than 18 years.
- Pregnant females and females on oral contraceptive pills.
- Patients with a history of hypertrophic scars or keloids.
- Patients with recurrent herpes infection or with present cutaneous infection and those with facial cancer.
- Patients with blood disorders and platelet abnormalities and chronic liver disease.
- Patients using systemic chemotherapy, anticoagulation therapy and antiplatelet agents.
Key Trial Info
Start Date :
November 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 7 2019
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT03308370
Start Date
November 1 2017
End Date
December 7 2019
Last Update
June 27 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut university hospitals
Asyut, Egypt